ASCRS 2020: Clinical trial results of KP1-121 0.25% for dry eye treatment

May 29, 2020
Alex Delaney-Gesing

Edward Holland, MD, director of Cornea Services at Cincinnati Eye Institute, speaks with Ophthalmology Times' David Hutton on the results of a clinical trial using KP1-121 0.25% (loteprednol etabonate) for dry eye treatment during the 2020 ASCRS virtual meeting.

 

See more ASCRS coverage here

Related Content:

ASCRS | News | Dry Eye